BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21705665)

  • 1. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.
    Glynn RW; Mahon S; Curran C; Callagy G; Miller N; Kerin MJ
    Oncologist; 2011; 16(7):949-55. PubMed ID: 21705665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
    Murthy SK; Magliocco AM; Demetrick DJ
    Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
    Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
    Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
    Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
    Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
    Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
    Fasching PA; Weihbrecht S; Haeberle L; Gasparyan A; Villalobos IE; Ma Y; Ekici AB; Wachter DL; Hartmann A; Beckmann MW; Slamon DJ; Press MF
    Breast Cancer Res Treat; 2014 May; 145(1):193-203. PubMed ID: 24682655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
    Qiao JH; Jiao DC; Lu ZD; Yang S; Liu ZZ
    Tumour Biol; 2015 Sep; 36(9):6833-8. PubMed ID: 25846735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2, TOP2A and chromosome 17 alterations in breast cancer.
    Beser AR; Tuzlali S; Guzey D; Dolek Guler S; Hacihanefioglu S; Dalay N
    Pathol Oncol Res; 2007; 13(3):180-5. PubMed ID: 17922046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
    Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
    BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
    Meng H; Chen R; Li W; Xu L; Xu L
    Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.
    Zaczek AJ; Markiewicz A; Seroczynska B; Skokowski J; Jaskiewicz J; Pienkowski T; Olszewski WP; Szade J; Rhone P; Welnicka-Jaskiewicz M; Jassem J
    Oncologist; 2012; 17(10):1246-55. PubMed ID: 22871798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
    Mitrović O; Čokić V; Đikić D; Budeč M; Vignjević S; Subotički T; Gulan M; Radović S; Furtula S
    Target Oncol; 2014 Dec; 9(4):367-79. PubMed ID: 24272208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
    Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
    Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrations of ERBB2 and TOP2A genes in breast cancer.
    Nielsen KV; Müller S; Møller S; Schønau A; Balslev E; Knoop AS; Ejlertsen B
    Mol Oncol; 2010 Apr; 4(2):161-8. PubMed ID: 19945923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.